Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Discovery of ALG-094103, a Liver-Targeted and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Liver Cancer

Friday, November 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of ALG-094103, a novel small molecule PD-L1 inhibitor specifically designed for liver cancer treatment. This compound is notable for its liver-targeted approach and oral bioavailability, which may improve patient compliance and therapeutic outcomes. The development reflects ongoing efforts to address significant gaps in liver cancer therapies.
Price reaction · baseline $18.6925 (2023-11-03T18:45:00.000Z) · hit during market hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of a new liver-targeted PD-L1 inhibitor.
  • Potential for oral bioavailability enhances treatment options.
  • Focus on liver cancer treatment aligns with unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-094103?

ALG-094103 is a newly discovered liver-targeted PD-L1 inhibitor for liver cancer.

How does ALG-094103 work?

It functions as a small molecule inhibitor targeting PD-L1 to enhance immune response against liver cancer.

What are the benefits of ALG-094103?

Its liver-targeted design and oral bioavailability may improve treatment efficacy and patient adherence.

What type of cancer is ALG-094103 aimed at?

ALG-094103 is specifically aimed at treating liver cancer.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-094103 liver cancer PD-L1 inhibitor oral bioavailability biopharma
Last updated: Nov 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →